CD44 and osteosarcoma: In a limited number of previous studies, it was confirmed that anlotinib suppressed osteosarcoma growth and metastasis via dual blockade of VEGFR2 and MET (10), and anlotinib was also found to reverse multidrug resistance (MDR) in osteosarcoma by inhibiting p-glycoprotein (PGP1) function (24).